Last reviewed · How we verify
MEDI-551
At a glance
| Generic name | MEDI-551 |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Myasthenia Gravis Inebilizumab Trial (PHASE3)
- N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders (PHASE2, PHASE3)
- A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies (PHASE1, PHASE2)
- MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma (PHASE2)
- Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis (PHASE1)
- Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma (EARLY_PHASE1)
- Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas (PHASE1, PHASE2)
- A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI-551 CI brief — competitive landscape report
- MEDI-551 updates RSS · CI watch RSS
- MedImmune LLC portfolio CI